Literature DB >> 11135214

Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.

Y Nakamoto1, T Higashi, H Sakahara, N Tamaki, M Kogire, R Doi, R Hosotani, M Imamura, J Konishi.   

Abstract

BACKGROUND: Positron emission tomography (PET) using (18)F-fluoro-2-deoxy-D-glucose (FDG) has been used for the evaluation of various tumors, but accumulation in inflammatory lesions makes it a controversial modality. The aim of this study was to investigate the usefulness of delayed scanning in differentiation between malignant and benign lesions in the pancreas.
METHODS: Forty-seven patients with suspected pancreatic carcinoma were studied by FDG-PET. All patients received approximately 370 megabequerels of FDG after a transmission scan, and an emission scan was performed 1 hour and 2 hours later for all patients. A subset of 19 patients was also scanned at 3 hours postinjection. The standardized uptake value (SUV) was determined, and the retention index was calculated by dividing the increase in the SUV between 1 hour and 2 hours postinjection by the SUV at 1 hour postinjection.
RESULTS: Of 27 malignant lesions, the SUVs of 22 lesions increased at 2 hours postinjection, whereas the FDG uptake in 17 of 20 benign lesions decreased. The SUVs at 3 hours postinjection were higher than those at 2 hours postinjection in 9 of 14 malignant lesions and in 2 of 5 benign lesions. Malignant lesions showed a higher retention index than benign lesions (mean +/- standard deviation: 12. 36 +/- 13.37 and -7.05 +/- 17.28, respectively; P < 0.0001). Applying an SUV of 2.5 at 1 hour postinjection with the cut-off value for the differentiation between malignant and benign lesions caused one false negative result and seven false positive results, with a diagnostic accuracy of 83.0% (39 of 47 patients). However, combining the retention index with the SUV obtained at 2 hours postinjection provided a higher diagnostic accuracy (91.5%; 43 or 47 patients) than the SUV alone. The false negative rate remained constant when the retention index was taken into account. Images at 3 hours postinjection usually were unhelpful in differentiating further between malignant lesions and benign lesions.
CONCLUSIONS: The current data suggest that delayed FDG-PET scanning at 2 hours postinjection may contribute to differentiation between malignant and benign lesions in the pancreas. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11135214     DOI: 10.1002/1097-0142(20001215)89:12<2547::aid-cncr5>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  55 in total

Review 1.  Recent advances in the surgical treatment of pancreatic cancer.

Authors:  A Shankar; R C Russell
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 2.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

3.  Intraductal oncocytic papillary neoplasm of the pancreas shows strong positivity on FDG-PET.

Authors:  Takehiro Noji; Satoshi Kondo; Satoshi Hirano; Yoshiyasu Ambo; Eichi Tanaka; Chietsugu Katoh; Eriko Tsukamoto; Nagayoshi Tamaki; Hiroyuki Katoh
Journal:  Int J Gastrointest Cancer       Date:  2002

4.  Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Atsushi Tani; Yoriko Kajiya; Shunji Shimaoka; Akio Matsuda; Tatsuyuki Nioh; Tohru Nihara; Toyokuni Suenaga; Sadao Tanaka; Hiroshi Shirahama; Michiyo Higashi; Chihaya Koriyama
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

5.  FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.

Authors:  Zhen Wang; Jun-Qiang Chen; Jin-Lu Liu; Xin-Gan Qin; Yuan Huang
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

6.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

Review 7.  PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.

Authors:  Keigo Endo; Noboru Oriuchi; Tetsuya Higuchi; Yasuhiko Iida; Hirofumi Hanaoka; Mitsuyuki Miyakubo; Tomohiro Ishikita; Keiko Koyama
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

8.  Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.

Authors:  Stefan Heinrich; Gerhard W Goerres; Markus Schäfer; Markus Sagmeister; Peter Bauerfeind; Bernhard C Pestalozzi; Thomas F Hany; Gustav K von Schulthess; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

9.  Significance of FDG-PET in Identification of Diseases of the Appendix - Based on Experience of Two Cases Falsely Positive for FDG Accumulation.

Authors:  Shimpei Ogawa; Michio Itabashi; Shingo Kameoka
Journal:  Case Rep Gastroenterol       Date:  2009-04-29

10.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.

Authors:  Christophe Van de Wiele; Vibeke Kruse; Peter Smeets; Mike Sathekge; Alex Maes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.